Biogen's experimental treatment showed efficacy following a gene therapy developed by Novartis.
1 report, 0 independent
Updated Jun 26
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Biogen's experimental treatment showed efficacy following a gene therapy developed by Novartis.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Novartis
Swiss-American multinational pharmaceutical corporation
-
Biogen
American multinational biotechnology company
Nothing else this week.
Related events
- The FDA approved various advanced therapies, including oral medication from Roche, a gene-targeting drug from Biogen, and a one-time gene therapy from Novartis.
- Bristol-Myers Squibb paused clinical trials following clinical setbacks reported by Novartis.
- Novartis conducted REMODEL trials for remibrutinib.
- Novartis acquired Regulus Therapeutics in April, while also reportedly weighing a potential deal with Avidity Biosciences.
Coverage
Newest first; wire copies grouped- Unknown outlet